HC Wainwright Forecasts Weaker Earnings for Rockwell Medical

Rockwell Medical, Inc. (NASDAQ:RMTI) – Investment analysts at HC Wainwright dropped their Q2 2025 earnings per share (EPS) estimates for shares of Rockwell Medical in a research report issued to clients and investors on Monday, November 25th. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.01) per share for the quarter, down from their prior estimate of $0.02. HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at $0.01 EPS.

RMTI has been the topic of a number of other research reports. StockNews.com cut shares of Rockwell Medical from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Rodman & Renshaw started coverage on shares of Rockwell Medical in a report on Thursday, November 14th. They issued a “buy” rating and a $5.00 price objective on the stock. Finally, RODMAN&RENSHAW upgraded shares of Rockwell Medical to a “strong-buy” rating in a report on Thursday, November 14th.

Rockwell Medical Price Performance

Shares of RMTI stock opened at $2.25 on Tuesday. The business’s fifty day moving average is $3.46 and its 200 day moving average is $2.66. The company has a quick ratio of 2.00, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The stock has a market cap of $72.72 million, a price-to-earnings ratio of -45.00 and a beta of 1.50. Rockwell Medical has a twelve month low of $1.16 and a twelve month high of $5.15.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. XTX Topco Ltd raised its stake in shares of Rockwell Medical by 45.7% in the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after purchasing an additional 8,922 shares during the last quarter. Concurrent Investment Advisors LLC purchased a new position in Rockwell Medical in the 3rd quarter worth about $40,000. Verus Capital Partners LLC bought a new position in Rockwell Medical during the 3rd quarter valued at about $51,000. State Street Corp boosted its holdings in shares of Rockwell Medical by 21.5% during the 3rd quarter. State Street Corp now owns 95,004 shares of the company’s stock valued at $377,000 after acquiring an additional 16,800 shares during the last quarter. Finally, Barclays PLC purchased a new stake in shares of Rockwell Medical during the 3rd quarter valued at about $90,000. 23.31% of the stock is owned by hedge funds and other institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.